


Amendments to the Claims

1. (Currently Amended) A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

R^1 is H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} thioalkyl, cyano, halo, C_{3-7} cycloalkyl, $-C_{1-6}$ alkylene- C_{3-7} cycloalkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is $C(D)NR^3R^4$, D' , $D''(R^3)(R^4)$ or $CH_2NR^3R^4$

D' is CH_2 or a bond;

D'' is C, C-OH or CH

wherein

said C is attached to R^3 by a single or double bond;

said C is attached to R^4 by a single or double bond;

provided that

C is not attached to both R^3 and R^4 by double bonds;

said CH is attached to R^3 and R^4 by single bonds;

said C of C-OH is attached to R^3 and R^4 by single bonds;

D is O or S;

R^3 and R^4 are each independently selected from the group consisting of H,

C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-6}$ hydroxyalkyl, $-C_{1-4}$ alkylene-O- C_{1-4} alkyl, $-C_{1-3}$ alkylene- C_{1-6} thioalkyl, $-C_{2-6}$ alkylidene-(C_{1-4} alkoxy) $_2$, C_{3-7} cycloalkyl, $-C_{1-6}$ alkylene- C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{3-6} alkynyl, $-C_{1-6}$ alkylene-CN, $-C_{1-6}$ alkylene-heterocyclo and $-C_{1-6}$ alkylene-aryl;

10/772,027 / CT2662 DIV3

wherein said aryl of said $-C_{1-6}$ alkylene-aryl is optionally substituted with one to three of the same or different substituents selected from the group consisting of fluoro, chloro, bromo, cyano, nitro, C_{1-4} alkyl and C_{1-3} alkoxy;

or

R^3 and R^4 together with the nitrogen to which they are attached form a five or six-membered heterocycle,

said heterocycle optionally containing one additional heteroatom

selected from the group consisting of N, S and O; and

said heterocycle optionally substituted with one or more groups selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, aryl, $-C_{1-4}$ alkylene-aryl, pyridyl and halogen;


wherein said aryl of said $-C_{1-4}$ alkylene-aryl is

optionally substituted with one to three of the same or different substituents selected from the group consisting of fluoro, chloro, bromo, cyano, nitro and C_{1-3} alkoxy;

X is C;

Y is C;

A is




wherein

X^1 is N and is attached to X;

Y^1 is N and is attached to Y;

G is



wherein

Y^2 is CE^1 and is attached to Y^1 ;

J is a bond;

Z^1 is CE^3 and is attached to Z;

wherein

E^1 and E^3 together form C_4 -alk(en)ylene;

optionally substituted with halogen, -CN,

C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, substituted or unsubstituted phenyl, hydroxy, C_1 - C_4 alkoxy, SH, C_1 - C_4 thioalkyl, NH_2 , $NH(C_1$ - C_4 alkyl) or $N(C_1$ - C_4 alkyl) $_2$;

Z is N-V, wherein V is phenyl, 2-pyridyl or 3-pyridyl substituted with two to three of the same or different ~~substituents~~ substituents selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_6 thioalkyl, C_1 - C_4 haloalkyl, halogen, $N(C_1$ - C_4 alkyl) $_2$ and CN.

2. (Currently Amended) A compound according to claim 1 wherein V is phenyl or 3-pyridyl and is substituted with two to three of the same or different ~~substituents~~ substituents selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_6 thioalkyl, C_1 - C_4 haloalkyl, halogen, $N(C_1$ - C_4 alkyl) $_2$ and CN; said substituents attached at the 2, 4 or 6-positions of said phenyl or said 3-pyridyl.
3. (Currently Amended) A compound according to claim 1 wherein V is 2-pyridyl and is substituted with two of the same or different ~~substituents~~ substituents selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_6 thioalkyl, C_1 - C_4 haloalkyl, halogen, $N(C_1$ - C_4 alkyl) $_2$ and CN; said substituents attached at the 3 and 5-positions of said 2-pyridyl.
4. (Original) A compound according to claim 1 wherein R^1 is C_1 - C_6 alkyl or C_1 - C_4 haloalkyl.
5. (Original) A compound according to claim 1 wherein R^1 is methyl or trifluoromethyl.
6. (Original) A compound according to claim 1 wherein R^2 is $C(D)NR^3R^4$ and D is O.

BEST AVAILABLE COPY

10/772,027 / CT2662 DIV3

7. (Original) A compound according to claim 1 wherein R^2 is $CH_2N R^3 R^4$.
8. (Original) A compound according to claim 1 wherein R^2 is $D' - D''(R^3)(R^4)$, D is a bond and D'' is C-OH.
9. (Original) A compound according to claim 1 wherein R^2 is $D' - D''(R^3)(R^4)$, D is a bond and D'' is C or CH.
10. (Original) A compound according to claim 1 wherein R^3 and R^4 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-6}$ hydroxyalkyl, $-C_{1-4}$ alkylene-O- C_{1-4} alkyl, $-C_{1-3}$ alkylene- C_{1-6} thioalkyl, $-C_{2-6}$ alkylidene- $(C_{1-4}$ alkoxy) $_2$, C_{3-7} cycloalkyl, $-C_{1-6}$ alkylene- C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{3-6} alkynyl and $-C_{1-6}$ alkylene-CN.
11. (Original) A compound according to claim 1 wherein R^3 and R^4 together with the nitrogen to which they are attached form a five or six-membered heterocycle.
12. (Original) A compound according to claim 1 wherein V is 2, 4, 6-trimethylphenyl.
13. (Original) A compound according to claim 1 wherein V is 2,4-dichlorophenyl.
14. (Original) A compound according to claim 1 wherein E^1 and E^3 together form C_4 -alk(en)ylene optionally substituted with halogen.
15. (Original) A compound or pharmaceutically acceptable salt of solvate thereof selected from the group consisting of
Cyclopropylmethyl-(2,2,2-trifluoro-ethyl)-[2-trifluoromethyl-8-(2,4,6-trimethylphenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-ylmethyl]-amine;
5-Fluoro-2-methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid ethyl ester;
2-Ethyl-5-fluoro-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid ethyl ester;

10/772,027 / CT2662 DIV3

2-Ethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid ethyl ester;

2-Trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid ethyl ester;

8-(2,4-Dichloro-phenyl)-2-methyl-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid ethyl ester;

[2-Trifluoromethyl-8-(2,4,6-trimethylphenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-yl]-methanol;

[8-(2,4-Dichlorophenyl)-2-trifluoromethyl-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-yl]-methanol;

3-Chloromethyl-2-trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene;

5-Fluoro-2-methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

2-Methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

2-Ethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

2-trifluoromethyl-8-(2,4,6-trimethylphenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

8-(2,4-Dichloro-phenyl)-2-methyl-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

2-Ethyl-5-fluoro-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]indene-3-carboxylic acid cyclopropylmethyl-propyl-amide;

Cyclopropylmethyl-[5-fluoro-2-methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-ylmethyl]-propyl-amine;

Cyclopropylmethyl-[2-ethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-ylmethyl]-propyl-amine;

Cyclopropylmethyl-propyl-(trifluoromethyl-trimethylphenyl-8*H*-1,3a,8-triaza-cyclopenta[*a*]inden-3-ylmethyl)-amine;

Cyclopropylmethyl-[2-ethyl-5-fluoro-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,8-triaza-

10/772,027 / CT2662 DIV3

cyclopenta[*a*]inden-3-ylmethyl]-propyl-amine; and
Cyclopropylmethyl-(2,2,2-trifluoro-ethyl)-[2-trifluoromethyl-8-(2,4,6-trimethylphenyl-8*H*-
1,3a,8-triaza-cyclopenta[*a*]inden-3-ylmethyl]-amine.

16. (Currently Amended) A method of treating depression[;] and anxiety, ~~affective disorders, post-traumatic stress disorder, post-operative stress, headache, drug addiction, eating disorders and obesity, sudden death due to cardiac disorders, irritable bowel syndrome, hypertension, syndrome X, inflammatory disorders, stress-induced immune suppression, infertility, stress-induced insomnia and other sleep disorders, seizures, epilepsy, stroke and cerebral ischemia, traumatic brain injury, yet other disorders requiring neuroprotection, drug or alcohol withdrawal symptoms, other disorders including tachycardia, congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, ulcers, diarrhea and post-operative ileus~~ comprising the administration of a pharmaceutical composition comprising a compound according to claim 1.